Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results